New Pathway for Influenza Vaccine Development
Author Information
Author(s): Ataca Sila, Sangesland Maya, de Paiva Fróes Rocha Rebeca, Torrents de la Peña Alba, Ronsard Larance, Boyoglu-Barnum Seyhan, Gillespie Rebecca A., Tsybovsky Yaroslav, Stephens Tyler, Moin Syed M., Lederhofer Julia, Creanga Adrian, Andrews Sarah F., Barnes Ralston M., Rohrer Daniel, Lonberg Nils, Graham Barney S., Ward Andrew B., Lingwood Daniel, Kanekiyo Masaru
Primary Institution: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Hypothesis
Can a subdominant immunoglobulin germline-encoded motif be engaged to generate cross-reactive B cells against influenza hemagglutinin?
Conclusion
The study demonstrates that immunization can shift antibody responses from a predominant germline-encoded response to a broader cross-reactive response.
Supporting Evidence
- Immunization with a non-cognate group 2 HA stem enriched B cells harboring the IGHD3-9 gene.
- Antibodies from the study bound and neutralized various influenza A viruses.
- Findings suggest a new approach for vaccine regimens to engage broader B cell responses.
Takeaway
Scientists found a way to help the immune system make better antibodies against the flu by using a special vaccine strategy.
Methodology
Transgenic mice were immunized with group 2 and group 1 hemagglutinin stem proteins to study antibody responses.
Potential Biases
The use of murine light chains instead of human light chains may introduce bias in the immune response.
Limitations
The study's findings may not fully apply to humans due to the use of a mouse model and the potential competition from other B cells in human immune responses.
Participant Demographics
Transgenic IGHV1-69 mice were used in the study.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website